Treatment of macular edema secondary to branch retinal vein occlusion with sub-tenon triamcinolone acetonide injectio

Not Applicable

• Conditions: Macular edema following BRVO

• Registration Number: JPRN-UMIN000031215
• Lead Sponsor: Aichi Medicak University Department of Ophthalmology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

1) The subject eye has retinal disease except BRVO. 2) Transparency of the subject eye is turbid. 3) Those who have active ocular infection or inactive toxoplasmosis. 4) Those who have glaucoma or ocular hypertension, or medical histories of them. 5) Those who have histories of herpetic infection in their subject eyes. 6) Those who have uncontrollable systemic disease. 7) Those who are systemic debility, or have severe heart disease, severe cerebral blood flow disorder or cirrhosis. 8) Serum creatinine is 2.0 mg/dL or more. 9) Those who have undergone vitreous surgery to the subject eye or who are expected to undergo vitreous surgery. 10) Those who have undertaken the following treatment within 24 weeks or who are expected to be undergone. Administration of corticosteroid to thesubject eye below the Tenon capsule or retro-bulbar. Intravitreal of drug to the subject eye. Administration of immunosuppressant drug, immunomodulatory drug, antimetabolites drug and/or alkylating agents. Hyperbaric oxygen therapy or stellate ganglion block. Hemodialysis or peritoneal dialysis. 11) Those who have received laser or intraocular surgery in the subject eye within 12 weeks or who are expected to undergo them. 12) Those who have received treatments which are corticosteroid, oral carbonic anhydrase inhibitor, warfarin, heparin, heparin analogue, selective thrombin inhibitor, direct thrombin inhibitors or(/and) FXa inhibitors within 4 weeks. Those who are expected to undergo these therapies. 13) Those who are planning of ophthalmic surgery during the observation period. 14) Those who have drug allergy to the drugs which are used in this study. 15) Those who cannot sufficient dilate pupil for inspection. 16) Pregnant or lactating women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified